Subscribe to Newsletter
Research & Development Adverse effects, Medical research

Do No Harm

A novel study has examined the differential effects of various THC:CBD ratios, using widely available chemovars (1). The team assessed 159 regular cannabis users before, immediately after, and one hour after ad libitum administration of one of three randomly assigned cannabis flower chemovars: THC-dominant (24% THC, 1% CBD), THC+CBD (9% THC, 10% CBD), and CBD-dominant (1% THC, 23% CBD). Plasma cannabinoids, as well as positive (high, elation) and negative (paranoia and anxiety) subjective effects were measured at each time point. 

As expected, researchers found that participants who used the CBD-dominant and THC + CBD chemovars had significantly less THC and more CBD in plasma samples than participants who used the THC-dominant chemovar. More interestingly, the THC + CBD chemovar group was associated with similar levels of positive subjective effects as the THC-dominant chemovar – but, crucially, with significantly less paranoia and anxiety.

Receive content, products, events as well as relevant industry updates from The Cannabis Scientist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. L Gibson et al., Addict Biol (2021). Online ahead of print. Available at: https://bit.ly/3kWe2Cd
About the Author
Phoebe Harkin
Register to The Cannabis Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Cannabis Scientist magazine

Register